『Mounjaro: Who Loses the Most Weight?』のカバーアート

Mounjaro: Who Loses the Most Weight?

Mounjaro: Who Loses the Most Weight?

無料で聴く

ポッドキャストの詳細を見る

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
#Mounjaro #Tirzepatide #GLP1 #WeightLoss #obesitymedicine Why do two people on the same Mounjaro dose get completely different results? In this video, I break down a study of more than 3,000 people with type 2 diabetes from the SURPASS 1–4 trials. It looked at who is most likely to lose 15% or more of their body weight on tirzepatide (Mounjaro / Zepbound), and why.You'll learn the 7 factors that predicted the biggest weight loss. Several of them are things you can change, sometimes before your first injection. I also cover what newer research says about Ozempic and Wegovy, why real-world results are lower than trial results, and the 6-month check-in that tells you whether you're on track.📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.comTIMESTAMPS0:00 Same drug, very different results1:15 Mounjaro vs Zepbound vs Ozempic explained2:19 What the SURPASS study measured3:32 Factor 1: Sex4:36 Factor 2: Age (and muscle loss)6:32 Factor 3: Your starting blood sugar8:36 Factor 4: Your cholesterol9:32 GLP-1 Masterclass10:12 Factor 5: Your other medications11:41 Factor 6: Dose12:34 Factor 7: Race and ethnicity13:29 Surprise: starting weight didn't matter13:58 Does this apply to Ozempic and Wegovy?15:26 The limits of this research16:36 7 steps to improve your odds19:52 Free GLP-1 Diet Cookbook + what's nextREFERENCESMałecki MT, Batterham RL, Sattar N, et al. Predictors of ≥15% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1–4. Diabetes Care. 2023;46(12):2292-2299. doi:10.2337/dc23-1135Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36.Aronne LJ, Horn DB, Kokkinos AD, et al. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026;139(7):913-921. doi:10.1016/j.amjmed.2026.03.010Powell W, Song X, Mohamed Y, et al. Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data. Obesity (Silver Spring). 2023;31(10):2482-2492. doi:10.1002/oby.23859Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729.Sattar N, Frühbeck G, Andreelli F, et al. Weight reduction with tirzepatide varied meaningfully by baseline HbA1c category in adults with overweight or obesity and type 2 diabetes in SURMOUNT-2. Diabetes Care. 2025;48(11):e136-e137. doi:10.2337/dc25-1442Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024.Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101(6):1320S-1329S.Mechanick JI, Butsch WS, Christensen SM, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025;26(1):e13841.Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48.Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません